Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
NCT Number: NCT01541800
MicroRNAs are small molecules which have recently been discovered in cells. They are known to be responsible for the normal development of cells and when they are disrupted can contribute to the development of cancer. Many previous studies have been done evaluating the expression of microRNAs in normal tissues as well as a wide variety of cancers.
Recently, microRNAs from tumor cells have been detected circulating in the blood of patients with cancer. This presents a novel opportunity to use microRNAs in the blood as an early predictor of cancer as well as a marker of response to therapy. No previous studies have been performed evaluating microRNAs in the blood or cerebrospinal fluid of patients with childhood cancers. We propose a feasibility study to evaluate the presence of microRNAs in the blood and cerebrospinal fluid of patients with central nervous system tumors, leukemia and lymphoma who are currently on chemotherapy and undergoing blood draws, lumbar punctures and/or reservoir taps for routine clinical care. If we're able to identify circulating microRNAs in this population of pediatric patients, we will build upon this data in proposing a future study.
Looking for future studies?
Notify Me3 year–21 year
All sexes
Observational
Chicago, Illinois, 60611, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Time frame: 1 year
Ann & Robert H Lurie Children's Hospital of Chicago
Other
A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06026046
Hematologic Diseases, Hemic and Lymphatic Diseases
Angers, France
View Trial DetailsNCT05763563
Hematologic Diseases, Hemic and Lymphatic Diseases
Tampa, Florida, United States
View Trial DetailsNCT01315132
Blood Protein Disorders, Cardiovascular Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04026737
Cardiotoxicity, Cardiovascular Diseases
Philadelphia, Pennsylvania, United States
View Trial Details